KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Eli Lilly (LLY) over the last 17 years, with Q3 2025 value amounting to $2.1 billion.

  • Eli Lilly's Capital Expenditures rose 5456.43% to $2.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 billion, marking a year-over-year increase of 4658.28%. This contributed to the annual value of $5.1 billion for FY2024, which is 4670.5% up from last year.
  • According to the latest figures from Q3 2025, Eli Lilly's Capital Expenditures is $2.1 billion, which was up 5456.43% from $1.7 billion recorded in Q2 2025.
  • Over the past 5 years, Eli Lilly's Capital Expenditures peaked at $2.1 billion during Q3 2025, and registered a low of $291.4 million during Q4 2021.
  • Its 5-year average for Capital Expenditures is $892.8 million, with a median of $738.2 million in 2023.
  • Its Capital Expenditures has fluctuated over the past 5 years, first crashed by 3591.38% in 2021, then soared by 11382.07% in 2023.
  • Quarter analysis of 5 years shows Eli Lilly's Capital Expenditures stood at $291.4 million in 2021, then surged by 71.83% to $500.7 million in 2022, then surged by 113.82% to $1.1 billion in 2023, then soared by 39.73% to $1.5 billion in 2024, then surged by 39.55% to $2.1 billion in 2025.
  • Its Capital Expenditures stands at $2.1 billion for Q3 2025, versus $1.7 billion for Q2 2025 and $1.5 billion for Q1 2025.